Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Authors

Michael Henderson

Published

July 20, 2015

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(15)00187-4

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Authors

Michael Henderson

Published

July 20, 2015

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(15)00187-4

Paper

Paper

Paper

Paper

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Supporters

Journal

Topics

DOI

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Supporters

Journal

Topics

DOI